Results 81 to 90 of about 1,459,532 (261)

CFTR modulators partially restore the epithelial interferome in Aspergillus infection to improve clinical outcomeResearch in context

EBioMedicine
Summary: Background: The impact of CFTR modulator therapy on host immunity and outcomes in people with Cystic Fibrosis (CF)-related Aspergillus lung disease is poorly defined.
Sarah L. Laverty, Imogen Felton, Michelle Casey, Benjamin Hopwood, Nicholas Simmonds, Darius Armstrong-James, Anand Shah, Peter Kelleher   +7 more
doaj   +1 more source

CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People With Cystic Fibrosis

Frontiers in Pharmacology, 2020
BackgroundCFTR modulators decrease some etiologies of CF airway inflammation; however, data indicate that non-resolving airway infection and inflammation persist in individuals with CF and chronic bacterial infections.
Katherine B. Hisert, Katherine B. Hisert, Timothy P. Birkland, Kelly Q. Schoenfelt, Matthew E. Long, Brenda Grogan, Suzanne Carter, W. Conrad Liles, Edward F. McKone, Lev Becker, Anne M. Manicone, Sina A. Gharib   +11 more
doaj   +1 more source

Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis

British Journal of Clinical Pharmacology, EarlyView.
Aim The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor–tezacaftor–ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population.
Paulette Magnas, Naim Bouazza, Frantz Foissac, Saïk Urien, Léo Froelicher‐Bournaud, Gabrielle Lui, Victoria Guillemart, Nicolas Carlier, Jennifer Da Silva, Johanna Fesenbeckh, Reem Kanaan, Isabelle Honoré, Clémence Martin, Jean‐Marc Treluyer, Vassilis Tsatsaris, Pierre‐Régis Burgel, Sihem Benaboud   +16 more
wiley   +1 more source

CFTR Modulator Therapy For Cystic Fibrosis

, 2020
IntroductionCystic fibrosis (CF) is the most common life-limiting autosomal recessive condition in Caucasians, affecting the respiratory system, digestive tract and all exocrine glands.
Galabova, M.; Department of Pediatrics, Second Pediatric Clinic, St. Marina University Hospital, Varna, Dobrudjanska, N.; Department of Pediatrics, Second Pediatric Clinic, St. Marina University Hospital, Varna, Nikolova, M.; Department of Pediatrics, Second Pediatric Clinic, St. Marina University Hospital, Varna, Koleva, K.; Department of Pediatrics, Second Pediatric Clinic, St. Marina University Hospital, Varna, Georgieva, M.; Department of Pediatrics, Second Pediatric Clinic, St. Marina University Hospital, Varna, Rasheva, N.; Department of Pediatrics, Second Pediatric Clinic, St. Marina University Hospital, Varna   +5 more
core  

Tobramycin pharmacokinetic and pharmacodynamic targets in people with cystic fibrosis

British Journal of Clinical Pharmacology, EarlyView.
Intravenous tobramycin is a first‐line treatment for Pseudomonas aeruginosa infection in people with cystic fibrosis (CF). Tobramycin exhibits concentration‐dependent activity; however, excess drug exposure can lead to nephrotoxicity and ototoxicity. While dosing typically targets serum peak (Cmax) and trough (Cmin) concentrations, the area under the ...
Kiera H. Harwood, Sarah Bannister, Stephen Duffull, April Martinez, Sarath Ranganathan, Shivanthan Shanthikumar, Amanda Gwee   +6 more
wiley   +1 more source

CFTR and Gastrointestinal Cancers: An Update

, 2022
Cystic Fibrosis (CF) is a disease caused by mutations in the CFTR gene that severely affects the lungs as well as extra-pulmonary tissues, including the gastrointestinal (GI) tract.
Blankenheim, Zachary, Patricia M. Scott, Robert T. Cormier, Zachary Blankenheim, Scott, Patricia M., Cormier, Robert T., Rahul Bhattacharya, Bhattacharya, Rahul   +7 more
core   +1 more source

A grumbling concern: A survey of gastrointestinal symptoms in cystic fibrosis in the modulator era [version 2; peer review: 1 approved, 4 approved with reservations]

NIHR Open Research
Background Gastrointestinal symptoms in cystic fibrosis (CF) are common and intrusive to daily life. Relieving gastrointestinal symptoms was identified as an important research priority and previously explored in an international survey in 2018. However,
Vinishaa Premakumar, Vigilius Gleetus, Zoe Elliott, Bu Hayee, Nicola J Rowbotham, Bethinn Evans, Helen Barr, Siobhán B Carr, Daniel Peckham, Alexander Horsley, Alan R Smyth, Natalie Goodchild, Rebecca J Calthorpe   +12 more
doaj   +1 more source

Cystic fibrosis and fat malabsorption: Pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective CFTR modulator therapy.

Nutrition in clinical practice
Cystic fibrosis (CF) is a progressive, genetic, multi-organ disease affecting the respiratory, digestive, endocrine, and reproductive systems. CF can affect any aspect of the gastrointestinal (GI) tract, including the esophagus, stomach, small intestine,
Catherine M. McDonald, Elizabeth Reid, John F Pohl, Tatiana Yuzyuk, Laura Padula, Kay Vavrina, Kimberly Altman   +6 more
semanticscholar   +1 more source

CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis

Pulmonary Therapy, 2021
Cystic fibrosis (CF) is the most common autosomal recessive disorder in Caucasian people and is caused by mutations in the gene encoding for the CF transmembrane conductance regulator (CFTR) protein. It is a multisystem disorder; however, CF lung disease
C. Benden, C. Schwarz
semanticscholar   +1 more source

A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients

British Journal of Clinical Pharmacology, EarlyView.
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly ...
Clara Laffitte Redondo, Venceslas Bourdin, Abd El Kader Ait Tayeb, Sihem Benaboud, Inès Martins, Caroline Joyau, Myriam Benhamida, Isabelle Sermet‐Gaudelus, Clémence Martin, Pierre Régis Burgel, Céline Verstuyft, Laurent Chouchana, Estelle Ayme‐Dietrich   +12 more
wiley   +1 more source